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and their combination are medicines of choice for treatment of
glaucoma in Russia. CONCLUSIONS: More attention is being
payed to prostaglandins and CAIs. The information of ophthal-
mologist and their patients about the cost of therapy is a very
important component for pharmacoeconomical decisions
together with medical effectiveness of treatment. But it is rather
low in Russia in whole.
EYE/EAR/SKIN DISEASES/DISORDERS
EYE/EAR/SKIN DISEASES/DISORDERS—Quality of
Life/Utility/Preference Studies
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OBJECTIVES: Evaluate association of National Eye Institute
Visual Functioning Questionnaire-25 (VFQ-25) score changes
with systemic comorbidities and visual acuity (VA) changes in
neovascular AMD patients in a phase I/II randomized controlled
trial of LucentisTM (ranibizumab; rhuFab V2). METHODS: At
baseline and three months, 57 patients completed the VFQ-25
(self-reported visual function) and VA was measured. The pres-
ence of seven comorbidities was recorded at baseline. VA score
(number of lines read) was converted to a weighted log of the
minimum angle of resolution (0.25 worse eye logMAR + 0.75
better eye logMAR). To estimate the relative association of
changes in VA and comorbidities with changes in VFQ-25 scores,
separate regression models of three-month changes in each sub-
scale score on the logMAR scores were developed for each
comorbidity. RESULTS: Mean number of comorbidities was 3,
including: 25 (44%) hypertension, 24 (42%) arthritis, 14 (25%)
hearing loss, 12 (21%) diabetes, 12 (21%) psychiatric disease,
12 (21%) back pain, 11 (19%) cancer. Due to small sample size,
only VA estimates in the regression were signiﬁcant after con-
trolling, individually, for the comorbidities. For all models, a
one-line (0.1 logMAR) worsening in VA was signiﬁcantly asso-
ciated with decreased subscale scores, particularly those related
to central vision (Near Activities, Distance Activities). VA alone
explained 11% of the variation in the VFQ-25 change between
baseline and 3 months in the Near Activities subscale. Inclusion
of an individual comorbidity improved the explanatory power
of the models slightly (r2): to 12% for hypertension, hearing loss,
diabetes, psychiatric disease, cancer, and back pain, 13% for
arthritis subjects, and 14% when summing all comorbidites a
patient had. CONCLUSIONS: Some selected VFQ-25 subscale
scores were decreased with the presence of visual impairment
and comorbidities. Systemic diseases should be included in VFQ-
25 assessments to control for differences between patients and
samples.
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OBJECTIVES: Assess the impact of atopic dermatitis (AD) on
parent’s quality of life (QoL) and use of health direct resources
in patients between 2 and 12 years old. METHODS: An obser-
vational burden-disease study of nine months of follow-up in
which AD patients 2 to 12 years old were included according to
Haniﬁn&Rajka diagnostic criteria. Four visits were conducted
per protocol (baseline, 3, 6, 9 months). Disease severity was
assessed by Investigator’s Global Assessment(IGA). Parents’ QoL
was assessed by Parents Index of Quality of Life Atopic Der-
matitis (PiQoL-AD) and by Visual Analogue Scale(VAS) of the
EQ-5D questionnaire. Use of direct resources in the last three
months were assessed retrospectively by medical ﬁles data or
direct interviews to patients’ parents. RESULTS: Results are
referred to baseline visit. A total of 240 children with AD were
included in the analysis, with mean age (SD) 5.3 (2.7), 52% were
boys. The most frequent careers were mothers (87.8%), 36.24
(4.9) years older (mean(SD)). 19.18% of patients had clear or
almost clear AD (IGA < 2), 31.25% had mild disease (IGA = 2),
37.91% had moderate disease (IGA = 3) and 11.68% had severe
or very severe disease (IGA = 4 or IGA = 5). Disease severity had
a signiﬁcant impact on parent’s QoL: mean scores of PIQoL-AD
questionnaire increased 4.9 points and VAS score decrease 16.28
points (p < 0.5), indicating a worsening health state. In the last
3 months, 79.69% of patients required medical assistance,
mainly from paediatricians or dermatologists; 81.84% pharma-
cological treatment and 24.11% laboratory tests, 17.61%
unscheduled visits and 12.73% went to the Emergency Depart-
ment. Use of direct resources increased with severity (p < 0.5).
CONCLUSIONS: Parents’ QoL tends to reduce progressively
from mild AD states while resource utilization increases pro-
gressively. Proper management of AD may help maintain patients
in less severe disease states, reducing the negative impact on
quality of life and on resource utilization.
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OBJECTIVES: The Dermatology Life Quality Index (DLQI) is a
widely-used HRQL measure. The instrument is intended for use
by patients with any skin disease. The aim of this study was to
assess the scaling properties of the DLQI and whether it is free
from differential item functioning (DIF). METHODS: DLQI
data collected in atopic dermatitis (AD) and psoriasis studies in
the UK were subjected to Rasch (one-parameter logistic item
response theory) analysis. Fit to the Rasch model was examined
via Chi2 statistics and assessments of DIF related to gender, age
and type of skin disease were made. RESULTS: Sample: Psoria-
sis study: n = 148 (49.7% male; mean age 45.1 +/- 14.9; mean
illness duration 20.9 +/- 13.5; mean DLQI score 8.7 +/- 6.7);
AD study: n = 286 (29.4% male; mean age 44.9 +/- 16.4; mean
illness duration 29.0 +/- 16.7; mean DLQI score 7.0 (+/-5.1).
The DLQI showed signiﬁcant misﬁt to the Rasch model in pso-
riasis and AD—indicating that the instrument is not unidimen-
sional. Several DLQI items exhibited DIF by age and gender.
Four of the ten items in the measure exhibited DIF by disease.
CONCLUSIONS: The DLQI was found to misﬁt the Rasch
model in both patient samples, indicating that it is unsafe to use
the total score on the measure. Its validity is further compro-
mised by DIF associated with age and gender which indicates
that items work differently with different subgroups of patients.
For example, the item “How much has your skin inﬂuenced the
